Key result
Landiolol is a promising ultrashort-acting beta-blocker for managing elevated heart rate and atrial fibrillation in intensive care patients, with a reduced risk of arterial hypotension.
Landiolol represents a promising agent for heart rate control in intensive care patients with atrial fibrillation due to its ultrashort action and favorable hemodynamic profile.
Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.
No takes yet. Share an insight, caveat, or question.
Rehberg et al. (2018) conducted a review in Atrial fibrillation. Landiolol was evaluated. Landiolol is a promising ultrashort-acting beta-blocker for managing elevated heart rate and atrial fibrillation in intensive care patients, with a reduced risk of arterial hypotension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: